SCHEMBL578901

SCHEMBL578901

CC(C)NS(=O)(=O)c1ccccn1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.51
SLC40A1 Q9NP59 3/20 0.46
GLO1 Q04760 3/20 0.46
S1PR1 P21453 1/20 0.43
KAT6A Q92794 1/20 0.42
KDM4E B2RXH2 2/20 0.42
PKM P14618 2/20 0.42
NLRP3 Q96P20 1/20 0.42
NFE2L2 Q16236 1/20 0.41
METAP2 P50579 1/20 0.41
NPSR1 Q6W5P4 1/20 0.40
CNR1 P21554 1/20 0.39
MMP2 P08253 1/20 0.39
KMT2A Q03164 1/20 0.39
ATM Q13315 2/20 0.39
TSHR P16473 1/20 0.39
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20094824 0.86 L3MBTL1 (0.49) L3MBTL1SLC40A1GLO1S1PR1KAT6A
SCHEMBL4622757 0.82 L3MBTL1 (0.45) L3MBTL1SLC40A1GLO1S1PR1KAT6A
SCHEMBL4622762 0.82 L3MBTL1 (0.45) L3MBTL1SLC40A1GLO1S1PR1KAT6A
SCHEMBL23036706 0.81 L3MBTL1 (0.51) L3MBTL1SLC40A1GLO1S1PR1KAT6A
SCHEMBL29706147 0.79 L3MBTL1 (0.56) L3MBTL1SLC40A1GLO1KAT6AKDM4E
SCHEMBL762825 0.79 L3MBTL1 (0.56) L3MBTL1SLC40A1GLO1KAT6AKDM4E
SCHEMBL17489126 0.78 L3MBTL1 (0.59) L3MBTL1SLC40A1GLO1KAT6AKDM4E
SCHEMBL22372476 0.77 L3MBTL1 (0.44) L3MBTL1SLC40A1GLO1S1PR1KAT6A
SCHEMBL7165302 0.77 L3MBTL1 (0.44) L3MBTL1SLC40A1GLO1S1PR1KAT6A
SCHEMBL7473562 0.77 L3MBTL1 (0.44) L3MBTL1SLC40A1GLO1S1PR1KAT6A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230165854-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY SHOUTI INC. 2023-06-01 US disclosed
US-20230165854-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY SHOUTI INC. 2023-06-01 US disclosed
EP-4092012-A1 PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER AMGEN INC. (US) 2022-11-23 EP disclosed
US-20220169611-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer AMGEN INC (US) 2022-06-02 US disclosed
US-20220125787-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY ANNAPURNA BIO, INC. 2022-04-28 US disclosed
US-20210179560-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer AMGEN INC (US) 2021-06-17 US disclosed
WO-2020073011-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY ANNAPURNA BIO, INC. (US) 2020-04-09 WO disclosed
EP-3483143-A1 PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER Amgen, Inc (US) 2019-05-15 EP disclosed
US-20180111956-A1 SYNTHESIS OF DESOSAMINES PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2018-04-26 US disclosed
US-20180066008-A1 MACROLIDES WITH MODIFIED DESOSAMINE SUGARS AND USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2018-03-08 US disclosed
US-8569341-B2 Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer AMGEN INC. (US) 2013-10-29 US disclosed
US-20120264736-A1 BENZENESULFONYL-CHROMANE, THIOCHROMANE, TETRAHYDRONAPHTHALENE AND RELATED GAMMA SECRETASE INHIBITORS SCHERING CORPORATION (US) 2012-10-18 US disclosed
US-20120184574-A1 INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT PTC THERAPEUTICS, INC. (US) 2012-07-19 US disclosed
US-20120135999-A1 COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT PTC THERAPEUTICS, INC. (US) 2012-05-31 US disclosed
EP-2417122-A1 INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT PTC Therapeutics, Inc. (US) 2012-02-15 EP disclosed
US-20110319378-A1 PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER AMGEN INC. (US) 2011-12-29 US disclosed
US-20110319378-A1 PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER AMGEN INC. (US) 2011-12-29 US disclosed
WO-2011153509-A1 PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER AMGEN INC. (US) 2011-12-08 WO disclosed
WO-2010117932-A1 INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT SCHERING CORPORATION (US) 2010-10-14 WO disclosed
US-20100256092-A1 BORON-CONTAINING SMALL MOLECULES ANACOR PHARMACEUTICALS, INC. (US) 2010-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180066008-A1 MACROLIDES WITH MODIFIED DESOSAMINE SUGARS AND USES THEREOF FUT6, MGAM, B3GNT2 L3MBTL1 3956/4885SLC40A1 4138/4885GLO1 1508/4885
US-20120135999-A1 COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT EIF2AK2, MAVS, ZC3HAV1 L3MBTL1 2286/4885SLC40A1 4343/4885GLO1 2881/4885
US-20110319378-A1 PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER MDM2, TP53, CDKN1A L3MBTL1 3993/4885SLC40A1 3261/4885GLO1 1038/4885
US-20120184574-A1 INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT IDO1, IRF3, MAVS L3MBTL1 2556/4885SLC40A1 4293/4885GLO1 1665/4885
US-20220169611-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer MDM2, TP53, CDKN1A L3MBTL1 3993/4885SLC40A1 3261/4885GLO1 1038/4885
US-20210179560-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer MDM2, TP53, CDKN1A L3MBTL1 3993/4885SLC40A1 3261/4885GLO1 1038/4885
US-20120264736-A1 BENZENESULFONYL-CHROMANE, THIOCHROMANE, TETRAHYDRONAPHTHALENE AND RELATED GAMMA SECRETASE INHIBITORS BACE1, PSEN1, BACE2 L3MBTL1 2558/4885SLC40A1 4133/4885GLO1 1784/4885
US-20180111956-A1 SYNTHESIS OF DESOSAMINES NANS, GALE, FUT6 L3MBTL1 3764/4885SLC40A1 1688/4885GLO1 51/4885
US-20220125787-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY APLNR, AGTR1, AGTR2 L3MBTL1 3775/4885SLC40A1 3876/4885GLO1 1207/4885
US-20230165854-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY APLNR, AGTR1, AGTR2 L3MBTL1 3775/4885SLC40A1 3876/4885GLO1 1207/4885
US-20100256092-A1 BORON-CONTAINING SMALL MOLECULES BCL6B, BCL6, BTD L3MBTL1 270/4885SLC40A1 1763/4885GLO1 4022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.